Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02173171 · ClinicalTrials.gov registry record
Registry Study for Talimogene Laherparepvec
A clinical trial of Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial, sponsored by Amgen.
- Completed
- Registry status
- 185
- Enrollment target
- 20
- Study locations
NCT02173171: Completed study of Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial, sponsored by Amgen.
NCT02173171 is a study of Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial that has completed, run by Amgen. The registered enrollment target is 185 participants. The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02173171, a study of Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- 185 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials
Primary Outcome
Long-term safety of talimogene laherparepvec will be assessed by reporting of related adverse events every 3 months. Related serious adverse events will be reported within 24 hours following investigator's knowledge of the event.
Conditions Studied
Interventions
- OTHER Information collection
Study Locations (20)
Florida
- Florida Hospital Memorial Division - Daytona Beach
- Baptist MD Anderson Cancer Center - Jacksonville
- Mount Sinai Comprehensive Cancer Center - Miami Beach
- H Lee Moffitt Cancer Center and Research Institute - Tampa
New Jersey
- Morristown Medical Center - Morristown
- Rutgers Cancer Institute of New Jersey - New Brunswick
North Carolina
- University of North Carolina Chapel Hill - Chapel Hill
- Wake Forest Baptist Health Medical Center - Winston-Salem
Alabama
- University of South Alabama Mitchell Cancer Institute - Mobile
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
California
- St Joseph Heritage Healthcare - Santa Rosa
Colorado
- University of Colorado Cancer Center - Aurora
Illinois
- Oncology Specialists SC - Park Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2010-04-27 |
| Est. Completion | 2021-09-23 |
What the finished NCT02173171 record still lists
NCT02173171 is an observational study that tracks outcomes without assigning an intervention. The registered 185 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial appearing as the primary indexed condition, and to 1 intervention - of which Information collection is the first listed.
NCT02173171 names 20 study sites across 15 states, led by Florida, New Jersey, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02173171 about?
NCT02173171 is a clinical study titled "Registry Study for Talimogene Laherparepvec". A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials
What is the current status of trial NCT02173171?
This trial is currently completed. The enrollment target is 185 participants. The study started on 2010-04-27. Estimated completion is 2021-09-23.
What conditions does trial NCT02173171 study?
This clinical trial studies the following conditions: Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial.
What interventions are being tested in trial NCT02173171?
The interventions under investigation include: Information collection (OTHER).
Who is sponsoring clinical trial NCT02173171?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02173171 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04041154 · 185 participants · NA
Behavioral and Neural Representations of Subjective Effort Cost
- NCT04484272 · 185 participants · NA
A Stress and Pain Self-management m-Health App for Adult Outpatients With Sickle Cell Disease
- NCT05020860 · 185 participants · Phase 2
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
- NCT05793541 · 185 participants · NA
Just-in-time Interventions for Reducing Short-term Suicide Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI